EP1891054A1 - Hydrates de sels alcalino-terreux d'irbesartan et leur preparation - Google Patents
Hydrates de sels alcalino-terreux d'irbesartan et leur preparationInfo
- Publication number
- EP1891054A1 EP1891054A1 EP06764732A EP06764732A EP1891054A1 EP 1891054 A1 EP1891054 A1 EP 1891054A1 EP 06764732 A EP06764732 A EP 06764732A EP 06764732 A EP06764732 A EP 06764732A EP 1891054 A1 EP1891054 A1 EP 1891054A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- irbesartan
- salt
- tetrahydrate
- hydrates
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to hydrates of alkaline earth salts of irbesartan and their preparation.
- Irbesartan is an angiotensin II AT1 receptor antagonist marketed as an antihypertensive drug and in the treatment of diabetic nephropathy.
- Irbesartan whose chemical name is 2-n-butyl-3 - [(2 '- (1H-tetrazol-5-yl) biphenyl-4-yl)] methyl] -1,3-diazaspiro [4,4 ] non-l-en-4-one of formula:
- Salts of irbesartan with an inorganic acid namely hydrobromide, hydrochloride and sulphate, are mentioned in US Pat. No. 6,162,922 and its European equivalent EP 1 060 165 B.
- EP 708 103 B discloses 2 tautomeric forms of irbesartan: A-form and B-form. This patent indicates that Form A is in the form of stable, non-hydroscopic needles having high electrostaticity. In addition, a new crystalline habit of rirbesartan form A is described in patent EP 1 089 994; in this patent, it is mentioned that irbesartan crystals of needle A are difficult to filter and dry and have poor flowability.
- Hydrates of the pharmaceutically acceptable alkaline earth metal salts of irbesartan have now been found which can be obtained easily from a process whose steps are carried out in aqueous solution.
- These are the hydrates of the calcium salt and the magnesium salt of irbesartan, more particularly the irbesartan calcium salt tetrahydrate and the irbesartan magnesium salt tetrahydrate.
- the subject of the present invention is the hydrates of the pharmaceutically acceptable alkaline earth salts of irbesartan, namely: the calcium and magnesium salts of irbesartan; the present invention is particularly relative to the tetrahydrate of the irbesartan calcium salt and the tetrahydrate of the irbesartan magnesium salt, and more particularly to the crystalline forms of these compounds.
- a sodium salt of irbesartan is prepared in aqueous solution; then
- the irbesartan sodium salt is displaced by the desired alkaline earth salt in an aqueous medium.
- the hydrate of the irbesartan alkaline earth salt thus formed is isolated by filtration; it is then dried.
- X-ray powder (X-ray) diffractograms were recorded for crystalline forms of irbesartan calcium salt tetrahydrate and irbesartan magesium salt tetrahydrate.
- the parameters of the crystal lattice were determined for each of the salts from their powder diffractogram.
- Tetrahydrate of the magnesium salt of irbesartan Tetrahydrate of the magnesium salt of irbesartan.
- Tetrahydrate of irbesartan calcium salt Tetrahydrate of irbesartan calcium salt.
- the subject of the present invention is also the tetrahydrate of the calcium or magnesium salt of irbesartan in crystalline form.
- Tetrahydrate of irbesartan calcium salt Tetrahydrate of irbesartan calcium salt.
- the irbesartan content in the irbesartan salt, determined by HPLC, is 81.34% (theoretical: 82.26%).
- the calcium content determined by ionic HPLC, is 3.86% (theoretical: 3.90%).
- Potentiometry makes it possible to quantify, by perchloric acid determination of the two basic functions of said salt, the amount of irbesartan present in the irbesartan salt.
- the water content of the salt obtained is measured by the method of Karl Fisher (15.4% or 4H2O) and by thermogravimetry: the thermogravimetry makes it possible to measure the loss of mass at 100 ° C that is to say the loss of water in mass: 12.96% is 4 moles of water per mole of product.
- Tetrahydrate of the magnesium salt of irbesartan Tetrahydrate of the magnesium salt of irbesartan.
- the irbesartan content in the salt is 82.39% (theoretical: 83.50%).
- the magnesium content determined by ionic HPLC, is 2.35% (theoretical: 2.87%).
- the water content of the salt obtained is measured by Karl Fisher (15.86% or 4H 2 O) and thermogravimetry: 12.26% or 4 moles of water per mole of product.
- the powder diffractogram Rx recorded for the salt obtained is shown in FIG. 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0505755A FR2886642B1 (fr) | 2005-06-06 | 2005-06-06 | Sels alcalino-terreux d'irbesartan et leur preparation |
PCT/FR2006/001267 WO2006131632A1 (fr) | 2005-06-06 | 2006-06-06 | Hydrates de sels alcalino-terreux d'irbesartan et leur preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1891054A1 true EP1891054A1 (fr) | 2008-02-27 |
Family
ID=35639476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06764732A Withdrawn EP1891054A1 (fr) | 2005-06-06 | 2006-06-06 | Hydrates de sels alcalino-terreux d'irbesartan et leur preparation |
Country Status (17)
Country | Link |
---|---|
US (1) | US7947842B2 (fr) |
EP (1) | EP1891054A1 (fr) |
JP (1) | JP2008542435A (fr) |
KR (1) | KR20080024473A (fr) |
CN (1) | CN101248061B (fr) |
AR (1) | AR054131A1 (fr) |
AU (1) | AU2006256678A1 (fr) |
BR (1) | BRPI0610933A2 (fr) |
CA (1) | CA2610665A1 (fr) |
FR (1) | FR2886642B1 (fr) |
HK (1) | HK1123793A1 (fr) |
IL (1) | IL187723A (fr) |
MX (1) | MX2007015426A (fr) |
RU (1) | RU2401266C2 (fr) |
TW (1) | TW200716099A (fr) |
UY (1) | UY29584A1 (fr) |
WO (1) | WO2006131632A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018843A1 (fr) * | 2006-08-08 | 2008-02-14 | Ulkar Kimya Sanayi Ve Ticaret As | Procédé de production de formes de sel utiles de composés de biphényl-tétrazole |
CN111175385B (zh) * | 2018-11-12 | 2023-02-07 | 珠海润都制药股份有限公司 | 一种厄贝沙坦中厄贝沙坦同分异构体检验方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ237476A (en) * | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
US5541209A (en) * | 1994-08-22 | 1996-07-30 | Bristol-Myers Squibb Company | Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative |
ES2309090T3 (es) | 2000-07-19 | 2008-12-16 | Novartis Ag | Sales de valsartan. |
CN1548421A (zh) * | 2003-05-22 | 2004-11-24 | 上海医药工业研究院 | 替米沙坦盐及其制备方法 |
SI21849A (sl) * | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava hidrokloridnih soli tetrazolskega derivata |
-
2005
- 2005-06-06 FR FR0505755A patent/FR2886642B1/fr not_active Expired - Fee Related
-
2006
- 2006-06-02 AR ARP060102315A patent/AR054131A1/es not_active Application Discontinuation
- 2006-06-05 TW TW095119885A patent/TW200716099A/zh unknown
- 2006-06-06 EP EP06764732A patent/EP1891054A1/fr not_active Withdrawn
- 2006-06-06 KR KR1020077028374A patent/KR20080024473A/ko not_active Application Discontinuation
- 2006-06-06 AU AU2006256678A patent/AU2006256678A1/en not_active Abandoned
- 2006-06-06 RU RU2007149526/04A patent/RU2401266C2/ru not_active IP Right Cessation
- 2006-06-06 WO PCT/FR2006/001267 patent/WO2006131632A1/fr active Application Filing
- 2006-06-06 CN CN2006800198798A patent/CN101248061B/zh not_active Expired - Fee Related
- 2006-06-06 JP JP2008515246A patent/JP2008542435A/ja active Pending
- 2006-06-06 MX MX2007015426A patent/MX2007015426A/es active IP Right Grant
- 2006-06-06 CA CA002610665A patent/CA2610665A1/fr not_active Abandoned
- 2006-06-06 BR BRPI0610933-0A patent/BRPI0610933A2/pt not_active IP Right Cessation
- 2006-06-07 UY UY29584A patent/UY29584A1/es unknown
-
2007
- 2007-11-28 IL IL187723A patent/IL187723A/en not_active IP Right Cessation
- 2007-12-05 US US11/950,555 patent/US7947842B2/en active Active
-
2009
- 2009-02-18 HK HK09101566.3A patent/HK1123793A1/xx not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2006131632A1 * |
Also Published As
Publication number | Publication date |
---|---|
UY29584A1 (es) | 2007-01-31 |
IL187723A0 (en) | 2008-08-07 |
CN101248061A (zh) | 2008-08-20 |
FR2886642B1 (fr) | 2008-05-30 |
AU2006256678A1 (en) | 2006-12-14 |
HK1123793A1 (en) | 2009-06-26 |
FR2886642A1 (fr) | 2006-12-08 |
CN101248061B (zh) | 2011-08-24 |
CA2610665A1 (fr) | 2006-12-14 |
WO2006131632A1 (fr) | 2006-12-14 |
RU2401266C2 (ru) | 2010-10-10 |
JP2008542435A (ja) | 2008-11-27 |
US7947842B2 (en) | 2011-05-24 |
IL187723A (en) | 2011-06-30 |
BRPI0610933A2 (pt) | 2010-08-03 |
TW200716099A (en) | 2007-05-01 |
AR054131A1 (es) | 2007-06-06 |
US20080096944A1 (en) | 2008-04-24 |
MX2007015426A (es) | 2008-02-19 |
KR20080024473A (ko) | 2008-03-18 |
RU2007149526A (ru) | 2009-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI338003B (en) | Process for the manufacture of organic compounds | |
EP3484895A1 (fr) | Formes à l'état solide de crisaborole | |
WO2009019303A2 (fr) | Procédé de préparation ou de purification de l'olmésartan médoxomil | |
JP4268871B2 (ja) | ピリミジノン化合物及びその薬剤として許容される塩の製造方法 | |
US7504516B2 (en) | Crystalline forms of candesartan cilexetil | |
EP1891054A1 (fr) | Hydrates de sels alcalino-terreux d'irbesartan et leur preparation | |
CA2603705A1 (fr) | Un procede pour la preparation de phenyltetrazoles | |
CA2060825A1 (fr) | Agent therapeutique | |
EA011713B1 (ru) | Получение гидрохлоридов производного тетразола | |
FR2618436A1 (fr) | Derives de piperidine, leur preparation et leur application en therapeutique | |
CN111683934A (zh) | (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途 | |
US20050165075A1 (en) | Novel amorphous form of valsartan | |
CA2628146A1 (fr) | Derives d'imidazole comme inhibiteur de la dimerisation de l'oxyde nitrique synthase | |
JP2023548185A (ja) | クラゾセンタン二ナトリウム塩の安定な結晶性水和物 | |
JP6276702B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ−[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン塩酸塩の固体形態 | |
JP2010538971A (ja) | バルサルタンを製造するために有効なバルサルタン塩の製造方法 | |
KR20070110617A (ko) | 로사탄의 개선된 제조방법 | |
WO2008018843A1 (fr) | Procédé de production de formes de sel utiles de composés de biphényl-tétrazole | |
CN1993354B (zh) | 四唑衍生物盐酸盐的制备 | |
EP2022790A1 (fr) | Procédé pour la préparation ou la purification d'olmésartan médoxomil | |
WO2005108395A1 (fr) | Polymorphe d'hydrochlorure de ziprasidone et procede de preparation | |
CA2576718A1 (fr) | Procede de preparation de la n-aminopiperedine et de ses sels | |
WO2006098705A1 (fr) | Procede de fabrication de composes du biphenyl-tetrazole | |
CZ20032319A3 (cs) | Způsob odstraňování trifenylmethanové chránící skupiny z 1-trityl-5-(4'-subst. aminomethyl-1,1' -bifenyl-2-yl)-1H-tetrazolů a způsob výroby draselné soli losartanu, irbesartanu a valsartanu s jeho použitím | |
WO2008041957A1 (fr) | PROCÉDÉ SERVANT À PRODUIRE UNE FORME CRISTALLINE PURE DE LA 2-n-BUTYL-3-[(2-(1H-TÉTRAZOL-5-YL)(1,1'-BIPHÉNYL)-4-YL)MÉTHYL]-1,3-DIAZASPIRO-[4,4]-NON-1-ÉN-4-ONE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080107 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
RAX | Requested extension states of the european patent have changed |
Extension state: RS Payment date: 20080107 Extension state: MK Payment date: 20080107 Extension state: HR Payment date: 20080107 Extension state: BA Payment date: 20080107 Extension state: AL Payment date: 20080107 |
|
17Q | First examination report despatched |
Effective date: 20100225 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20150615 |